Abundance of mitochondrial superoxide dismutase is a negative predictive biomarker for endometriosis-associated ovarian cancers.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ analysis
Carcinoma, Endometrioid
/ enzymology
Female
Humans
Immunohistochemistry
Middle Aged
Mitochondria
/ enzymology
Neoplasm Recurrence, Local
Neoplasm Staging
Ovarian Neoplasms
/ enzymology
Reactive Oxygen Species
/ metabolism
Superoxide Dismutase
/ analysis
Clear cell ovarian carcinoma
Endometrioid ovarian carcinoma
Endometriosis-associated ovarian cancer
Mitochondrial superoxide dismutase
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
30 Jan 2019
30 Jan 2019
Historique:
received:
29
11
2018
accepted:
15
01
2019
entrez:
1
2
2019
pubmed:
1
2
2019
medline:
9
2
2019
Statut:
epublish
Résumé
Endometrioid ovarian carcinoma and clear cell ovarian carcinoma are both classified as endometriosis-associated ovarian cancers (EAOCs). Despite the high rates of recurrence and mortality of EAOC, only a few prognostic biomarkers have been reported. Mitochondrial superoxide dismutase (SOD2) plays an important role in maintaining mitochondrial function through oxidative stress tolerance and contributes to chemotherapeutic resistance. To clarify the clinical significance of SOD2 in EAOC, SOD2 expression was semi-quantitatively investigated by immunohistochemical analysis in 61 primary EAOC cases, and the correlations between SOD2 expression and clinicopathological data and survival were analyzed. Forty-six (75%) cases expressed high levels of SOD2. High SOD2 expression was associated with a poor prognosis on both univariate and multivariate analyses after adjusting for variables such as age, International Federation of Gynecology and Obstetrics (FIGO) stage, blood markers, histological type, and completion of treatment. There were 14 fatalities from 15 recurrences among 46 cases with high SOD2 expression. In contrast, only one recurrence and no fatalities were seen among 15 cases with low SOD2 expression. Increased SOD2 expression is a predictive biomarker for worse prognosis in EAOC. The therapeutic efficacy of the current standard therapeutic protocol for EAOC is limited; thus, mitochondrial SOD2 should be a therapeutic target for SOD2-abundant EAOC.
Sections du résumé
BACKGROUND
BACKGROUND
Endometrioid ovarian carcinoma and clear cell ovarian carcinoma are both classified as endometriosis-associated ovarian cancers (EAOCs). Despite the high rates of recurrence and mortality of EAOC, only a few prognostic biomarkers have been reported. Mitochondrial superoxide dismutase (SOD2) plays an important role in maintaining mitochondrial function through oxidative stress tolerance and contributes to chemotherapeutic resistance.
METHODS
METHODS
To clarify the clinical significance of SOD2 in EAOC, SOD2 expression was semi-quantitatively investigated by immunohistochemical analysis in 61 primary EAOC cases, and the correlations between SOD2 expression and clinicopathological data and survival were analyzed.
RESULTS
RESULTS
Forty-six (75%) cases expressed high levels of SOD2. High SOD2 expression was associated with a poor prognosis on both univariate and multivariate analyses after adjusting for variables such as age, International Federation of Gynecology and Obstetrics (FIGO) stage, blood markers, histological type, and completion of treatment. There were 14 fatalities from 15 recurrences among 46 cases with high SOD2 expression. In contrast, only one recurrence and no fatalities were seen among 15 cases with low SOD2 expression.
CONCLUSION
CONCLUSIONS
Increased SOD2 expression is a predictive biomarker for worse prognosis in EAOC. The therapeutic efficacy of the current standard therapeutic protocol for EAOC is limited; thus, mitochondrial SOD2 should be a therapeutic target for SOD2-abundant EAOC.
Identifiants
pubmed: 30700285
doi: 10.1186/s12957-019-1565-0
pii: 10.1186/s12957-019-1565-0
pmc: PMC6354361
doi:
Substances chimiques
Biomarkers, Tumor
0
Reactive Oxygen Species
0
Superoxide Dismutase
EC 1.15.1.1
superoxide dismutase 2
EC 1.15.1.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
24Subventions
Organisme : Japan Society for the Promotion of Science
ID : KAKENHI Grant Number JP16k20187.
Références
Cancer. 2000 Jun 1;88(11):2584-9
pubmed: 10861437
Cancer Sci. 2008 Apr;99(4):653-8
pubmed: 18377417
Gynecol Oncol. 2008 Jun;109(3):370-6
pubmed: 18395777
Oncogene. 2010 Mar 25;29(12):1741-52
pubmed: 20062075
J Clin Pathol. 2010 Nov;63(11):962-6
pubmed: 20972242
Gynecol Oncol. 2012 Jan;124(1):164-9
pubmed: 22032835
Clin Cancer Res. 2012 May 15;18(10):2905-12
pubmed: 22465831
Stem Cells Dev. 2013 Feb 15;22(4):554-66
pubmed: 22974371
Trends Pharmacol Sci. 2013 Feb;34(2):126-35
pubmed: 23277337
Lancet Oncol. 2013 Aug;14(9):853-62
pubmed: 23845225
Oncol Rep. 2014 May;31(5):2157-64
pubmed: 24626613
Biochem J. 2014 Sep 15;462(3):475-87
pubmed: 25017630
Biochemistry. 1989 Oct 17;28(21):8653-8
pubmed: 2557905
Am J Transl Res. 2015 Feb 15;7(2):401-10
pubmed: 25901207
Jpn J Clin Oncol. 2015 Sep;45(9):884-91
pubmed: 26142437
Cancer Res. 2015 Nov 15;75(22):4973-84
pubmed: 26359457
Oncol Res. 2016;23(6):275-82
pubmed: 27131313
Sci Rep. 2016 May 09;6:25669
pubmed: 27157976
Sci Rep. 2016 May 16;6:25918
pubmed: 27181103
Ann Oncol. 2016 Dec;27(12):2184-2195
pubmed: 27681864
BMC Cancer. 2017 Jul 21;17(1):494
pubmed: 28732480
Mod Pathol. 2017 Dec;30(12):1748-1759
pubmed: 28776572
J Cancer. 2017 Aug 2;8(13):2532-2541
pubmed: 28900491
Oncotarget. 2017 Oct 31;8(59):100449-100458
pubmed: 29245991
Ecancermedicalscience. 2018 Jan 25;12:803
pubmed: 29456620
J Clin Invest. 1996 May 15;97(10):2268-76
pubmed: 8636406
Eur J Gynaecol Oncol. 1998;19(5):438-40
pubmed: 9863906